A phase 1 study of a novel tau PET imaging agent [18F]APN-1607
Latest Information Update: 29 Dec 2021
Price :
$35 *
At a glance
- Drugs Florzolotau (Primary)
- Indications Alzheimer's disease; Progressive supranuclear palsy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors APRINOIA Therapeutics
- 29 Dec 2021 New trial record